Article
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
Bioorganic & medicinal chemistry letters - 1 Jul 2016
Yu Wensheng, Coburn Craig A, Yang De-Yi, Meinke Peter T, Wong Michael, Rosenblum Stuart B, Chen Kevin X, Njoroge George F, Chen Lei, Dwyer Michael P, Jiang Yueheng, Nair Anilkumar G, Selyutin Oleg, Tong Ling, Zeng Qingbei, Zhong Bin, Ji Tao, Hu Bin, Agrawal Sony, Xia Ellen, Zhai Ying, Liu Rong, Kong Rong, Ingravallo Paul, Asante-Appiah Ernest, Nomeir Amin, Fells James, Kozlowski Joseph A
Abstract excerpt
HCV NS5A inhibitors have demonstrated impressive in vitro potency profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed dose combination regimen for the treatment of HCV infection. Herein, we describe research efforts that led to the discovery of a series of fused tricyclic core containing HCV NS5A inhibitors such as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.